SCM
PHAT icon

Sterling Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Sterling Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.3K Sell
1,198
-551
-32% -$6.96K ﹤0.01% 2227
2025
Q4 		$29K Sell
1,749
-410
-19% -$5.86K ﹤0.01% 2030
2025
Q3 		$25.4K Buy
2,159
+1,256
+139% +$13K ﹤0.01% 2025
2025
Q2 		$8.66K Buy
903
+341
+61% +$1.89K ﹤0.01% 2230
2025
Q1 		$3.52K Sell
562
-305
-35% -$1.85K ﹤0.01% 2328
2024
Q4 		$7.04K Buy
867
+761
+718% +$9.42K ﹤0.01% 2311
2024
Q3 		$1.92K Buy
+106
New +$1.48K ﹤0.01% 2202

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return